Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial

This publication has 11 references indexed in Scilit:

• Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
  New England Journal of Medicine, 2006
• Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
  The Lancet, 2005
• A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2005
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2004
• Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events
  Stroke, 2004
• Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
  JAMA, 2002
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
  The Lancet, 2001
• Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin
  American Heart Journal, 2000
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
  The Lancet, 1996
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993